Full Press Release Details
Appoints Jason Mills to the Board of Directors
Med-Tech Research Analyst & Public Company Executive to Bring Strategic Experience, Industry Relationships and Vision to the Board
PRAIRIE, Minn., December 22, 2025 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"),
a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced
the appointment of Jason Mills to its Board of Directors, effective as of December 18, 2025.
Mills currently serves as Executive Vice President of Strategy at NYSE-listed Penumbra, Inc., leading long-range planning, FP&A,
Business Development, and Investor Relations. Penumbra is the world's leading thrombectomy company, focused on developing the most
innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism,
and acute limb ischemia. Prior to joining Penumbra, he was a dedicated med-tech investment analyst for more than two decades. Mr. Mills
held the role of Managing Director and head of the medical technology equity research practice at Canaccord Genuity for over 13 years,
where he prepared financial models and financial forecasts, published research, and conducted due diligence on dozens of public and private
companies in the sector. He has earned awards for his equity research, including the #2 ranked Medical Devices analyst in The Wall
Street Journal's 2011 Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage
Analysts. He holds a BA in Economics from Yale University and Masters in Sports Administration from Ohio University.
are privileged to welcome Jason to NeuroOne with his strong background in med-tech in both corporate settings and as an industry investment
analyst," said Dave Rosa, CEO of NeuroOne. "Having known Jason since he was at Canaccord, I know he brings unparalleled and
invaluable experience and insights in med-tech. His firsthand knowledge of our industry, combined with his investment and capital markets
expertise, will be a critical resource as we progress on our clinical and corporate goals."
Buckman, Chairman of the Board of Directors, added, "In addition to his service on the Compensation and Nominating & Corporate
Governance Committees, Jason will help us expand the breadth and depth of our reach as a company transforming the diagnosis and treatment
of neurological disorders, positioning us to create additional value for our shareholders."
Medical Technologies Corporation (NASDAQ: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for
EEG recording, monitoring, ablation, drug delivery and stimulation solutions for patients suffering from epilepsy, Parkinson's
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve
patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders,
pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Group - MZ North America